Road Map for Business Continuity in Pharmaunwiredcp
The Indian pharma sector is the third largest in the world. It manufactures almost 60 per cent of the vaccines used globally, including important ones, such as those against diphtheria, tetanus, and pertussis required by the World Health Organisation (WHO). Furthermore, the country meets 90 per cent of the global demand for the vaccine against measles.
Currently, generic drugs are playing a crucial role in the fight against COVID–19. India has been meeting more than 20 per cent of the world and almost 50 per cent of the US’s generic drug requirements. Unfortunately, Indian manufacturers rely heavily on China for key starting materials (KSMs), intermediate and APIs with China catering to nearly 70 per cent of Indian pharma companies’ requirements.
The Indian pharma sector is an important component of the global healthcare infrastructure and is instrumental in saving millions of lives every year. However, the lockdown triggered by coronavirus disease (Covid-19) has caused disruptions in all sectors. Pharma sector has been jolted too but there is hope that things will ease, and growth will resume.
The Economic Times Next Normal in Pharma themed on ‘’Road Map for Business Continuity in Pharma’’ is trying to gather the entire pharma industry value chain for indispensable discussion to connect and shape the future.
The programme will feature panels, one-to-one discussions, and keynotes, with disrupters, government, consultants and pharma professionals debating at the platform. The Economic Times Next Normal In Pharma will witness key stakeholder across organizations to reveal a holistic view of the challenges and enable cross-fertilization of knowledge.
This Webinar would highlight the core challenges and how the Indian healthcare system can overcome from the same by focusing on aspects below
• Initial Business Continuity Plans & how they have panned out
• Pharma experimenting and mastering alternative channels to doctors
• Managing Information: Ability to translate huge amount of digital information and decision making as a result
• Evolving into a Healthcare Digital Ecosystem from a traditional Pharma Company
• Challenges in digitalisation and solution
• Digital initiatives that are here to stay in pharma ecosystem – innovating for the new normal?
• Way Forward for India’s pharmaceutical Connect to External stakeholders
Merck (India Cluster)
Managing Director Bayer Zydus Pharma and Country Division Head
South Asia – Pharmaceuticals
MD & CEO
Bharat Serums and Vaccines
Mckinsey & Company
India Oncology, Novartis
Boehringer Ingelheim India Pvt Ltd.
Managing Director & Global Chief Executive Officer
MD & CVP